4MOVING-BIOTECH
2.7.2024 07:31:32 CEST | Business Wire | Press release
4Moving Biotech (4MB), a clinical-stage subsidiary of 4P-Pharma specializing in immuno-inflammation and osteoarthritis, is pleased to announce the appointment of Luc Boblet as Chief Executive Officer. The company, having successfully completed its Phase I clinical trial and a preparatory in silico Phase 2 analysis, looks to Luc Boblet's seasoned expertise in biotech entrepreneurship and strategic development to guide the forthcoming stages of clinical proof of concept and early market access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701233556/en/
Luc Boblet, CEO OF 4Moving Biotech (Photo: Business Wire)
Luc Boblet, a biotech entrepreneur with two decades of experience, joins 4MB following his tenure at Egle Therapeutics, where his leadership was essential in advancing novel immunotherapies and securing a robust Series A funding backed by a big pharma strategic alliance. His previous roles included founding and leading companies such as H-IMMUNE - acquired by HiFiBIO - and Pathoquest, where he excelled in driving innovation, closing fundraising and forging strategic partnerships as instrumental catalyst of growth.
"Luc's appointment comes at a turning point for 4Moving Biotech as we have concluded a milestone Phase I trial for our leading drug candidate and are advancing strategic discussions with the FDA, toward potential accelerated approval" said Revital Rattenbach, founder and CEO of 4P-Pharma and co-founder of 4Moving. "His track record in steering biotech ventures and his strategic approach to partnerships will be invaluable as we advance our clinical programs and explore opportunities for pharma co-development and partnership."
As CEO of 4Moving Biotech, Luc Boblet's immediate focus will be on overseeing the design and implementation of the development strategy for the upcoming Phase II clinical trials, as well as cultivating partnerships that align with the company's vision for growth and patient access to innovative treatments.
Luc Boblet, CEO of 4Moving Biotech said: "The opportunity to lead 4Moving Biotech at this juncture is one that is aligned with my commitment to bringing pioneering therapies for untreated severe diseases. The company's progress in drug development and the potential to significantly improve patient outcomes in osteoarthritis is a strong foundation for future success. I am looking forward to applying my experience in corporate strategy business development to deliver our value proposal and establish meaningful partnerships."
About 4Moving Biotech
4Moving Biotech, a subsidiary of 4P-Pharma, is dedicated to developing advanced first in class therapies in the field of immuno-inflammation and osteoarthritis. With a commitment to improving patient care, 4MB is actively engaged in the clinical development of novel treatments poised to enhance quality of life for patients worldwide.
Biography of Luc Boblet, CEO of 4Moving Biotech.
Luc Boblet is a serial biotech entrepreneur with 20 years of experience in entrepreneurship, business development, corporate finance and early drug development. Luc is coming from Egle Therapeutics, spin out of Institut Curie dedicated to developing novel Regulatory T-cells based immunotherapies for oncology and autoimmune diseases, he has co-founded in early 2020. As a founding CEO, he built Egle Tx with a vision to become a game changer in the field of Tregs immunomodulation catalyzed by strategic alliance with Takeda Pharmaceutical and backed by 45M€ Series A from a high-quality syndicate of renowned international investors. Before creating Egle Tx, Luc co-founded and ran H-IMMUNE, start-up spun out of French Nuclear Agency (CEA), developing novel anti-check-point immunotherapies against T-effector and Tregs for oncology. He paved H-IMMUNE corporate path through partnerships with Pierre Fabre Laboratories and Norther Biologics and have exited H-IMMUNE through an acquisition by HiFiBIO in 2018. Before co-founding H-IMMUNE, Luc co-founded and ran Pathoquest, a start-up company spun out of Institute Pasteur, which develops disruptive unbiased NGS-based diagnostics in the field of infectious diseases. Under his guidance, Pathoquest raised two VC-backed rounds of financing, closed strategic collaborations and corporate partnerships with leading pharma companies (CERBA Laboratories and Covance), and launched several clinicals trials in France and the U.S.
From 2011 to 2015, he served on the board of directors of the BioAster Technological Research Institute.
He started his career in technology transfer, consulting in finance and business development for toxicogenomics R&D. Luc Boblet holds a biotech engineering degree, master’s degree in Virology and has been trained as a PhD in Virology from University Paris VII.
About 4Moving Biotech
Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
X: https://twitter.com/4Moving_Biotech
The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701233556/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lexon × Jeff Koons Unveil the Chromatic Collection: a Colorful New Chapter for the Acclaimed Balloon Dog Lamp and Balloon Dog Speaker24.3.2026 15:10:00 CET | Press release
Eight new models introduce vibrant color variations, expanding the collection’s appeal to new and existing collectors alike. Following the success of its 2025 inaugural edition, the Lexon × Jeff Koons collaboration enters a bold new era with the launch of the Chromatic Collection—a colorful evolution of its Balloon Dog Lamp and Balloon Dog Speaker. Pre-orders will be available starting March 24, 2026, exclusively on lexon-design.com as part of a time-limited edition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324498068/en/ Lexon x Jeff Koons — new Chromatic Collection Retaining the signature translucent body that reveals the technology within, the Chromatic Collection introduces eight models: Balloon Dog Lamps in Gold, Blue, Red, and Platinum, and Balloon Dog Speakers in Gold, Blue, Red, and White, reinforcing the collectible nature of the series, offering new audiences an entry point while giving existing collectors
iQmetrix Joins TM Forum as ODA Component Directory Partner, Giving Telecom Operators a Faster, Cleaner Path to Modern Commerce24.3.2026 15:00:00 CET | Press release
Platform’s Standards-Based Architecture Reduces Integration Risk and Accelerates Transformation for CSPs Worldwide iQmetrix, the global provider of Interconnected Commerce solutions purpose-built for telecom retail, today announced it has joined TM Forum and earned recognition as an Open Digital Architecture (ODA) Component Directory Partner. The achievement validates that iQmetrix aligns with the ODA vision and that its platform is built around standardized open APIs, modular cloud-native components, and interoperable architecture aligned with how leading operators are building their digital futures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324562860/en/ iQmetrix partners with TM Forum’s ODA Component Directory to accelerate open, future‑ready telecom transformation The recognition comes as communications service providers (CSPs) accelerate AI adoption and move away from integration-heavy legacy environments. For o
Miro Acquires Reforge to Help Organizations Navigate the Transition to AI24.3.2026 14:00:00 CET | Press release
Together, Reforge and Miro will provide a powerful and highly differentiated solution for teams that blends the tools and knowledge needed to innovate in the AI era Miro®, the AI Innovation Workspace for teams, today announced that it has acquired (subject to customary closing conditions) Reforge, an AI platform for product teams. The deal includes Reforge's team, learning platform, and AI-powered product development tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324623461/en/ Organizations are grappling with how to leverage AI to its full potential. In many cases, the problem is not how to code faster, but deciding what to build. That's the bottleneck slowing companies down today. Miro and Reforge are both solving this challenge for customers – tackling the need to build both at speed and with clear strategic direction. Miro brings a collaborative AI workflows platform that brings teams and AI together to plan, co
Xsolla and Stevenage FC Launch Charity Campaign With SpecialEffect to Make Gaming Accessible for All24.3.2026 14:00:00 CET | Press release
Donation Of 50 Accessible Setups Reinforces Xsolla’s Commitment To Inclusive Gaming Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, has partnered with Stevenage FC to launch a charity campaign with SpecialEffect in the United Kingdom, a charity dedicated to helping everyone to have the ability to enjoy video games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324722671/en/ Graphic: Xsolla Through the Official Partnership of Stevenage FC, Xsolla is donating the kit for the April 6th match vs Blackpool. SpecialEffect will be the primary kit brand for the match and will receive a percentage of the jersey sales leading up to the match and throughout the rest of the season. Xsolla will match donations from jersey sales, with the goal of using the funds to provide up to 50 Accessible Setups to disabled gamers at the end of the 2025-2026 season, and to support programs
SES Taps K2 Space to Accelerate Next-Gen MEO Satellite Network, meoSphere24.3.2026 14:00:00 CET | Press release
Next-generation Medium Earth Orbit (MEO) network is a multi-mission constellation targeted at meeting fast growing commercial and defense needs with flexible scaling approach. SES, a space solutions company, today announced it will deploy meoSphere, a next-generation medium Earth orbit (MEO) satellite network targeted for operation by 2030 and designed to significantly boost the company’s MEO network capacity. The program launches with a close collaboration designed for efficient satellite production. SES will pair its own software-defined payloads, being developed and manufactured in Luxembourg, with an initial 28 high-power satellite platforms developed by K2 Space, representing the first phase of the broader meoSphere rollout. The collaboration gives SES tighter control over key supply-chain elements, compresses the build timeline, and allows the company to manage schedules and costs with precision, laying the foundation for future scalability. meoSphere is SES’s next generation MEO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom